GLP-1 Peptides Explained: Semaglutide, Tirzepatide, and the Incretin Revolution

What This Guide Covers

GLP-1 receptor agonists have become among the most discussed medications in the world, driven by dramatic weight loss results from semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). This guide explains what GLP-1 is, how these medications work, what the clinical evidence shows, and what distinguishes the available compounds.

Unlike most peptides discussed on this site, GLP-1 agonists have extensive Phase III clinical data, FDA approval, and millions of patients’ worth of real-world experience. They represent what peptide therapeutics look like when they successfully navigate the full clinical development pipeline.

Who this guide is for, and who it isn’t for

This guide is for anyone who wants to understand GLP-1 medications from a scientific and evidence-based perspective. It is written for patients, researchers, and informed readers.

This guide is not a substitute for consulting a prescribing physician. GLP-1 agonists are prescription medications with real risks and contraindications.

What Is GLP-1?

GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone produced by L-cells in the small intestine in response to food intake. It plays several roles in metabolic regulation:

• Insulin secretion: GLP-1 stimulates glucose-dependent insulin release from pancreatic beta cells (it only increases insulin when blood sugar is elevated, reducing hypoglycemia risk)
• Glucagon suppression: reduces glucagon secretion, lowering blood sugar
• Gastric emptying: slows stomach emptying, contributing to satiety
• Appetite reduction: acts on brain centers (particularly the hypothalamus and brainstem) to reduce hunger
• Beta cell preservation: preclinical evidence suggests GLP-1 signaling supports pancreatic beta cell health

Natural GLP-1 has a half-life of approximately 2 minutes. It is rapidly degraded by the enzyme DPP-4. This is why therapeutic GLP-1 agonists require structural modifications to extend their duration of action.

The GLP-1 Agonist Medications

Semaglutide

Semaglutide is a modified GLP-1 analog manufactured by Novo Nordisk. Key modifications include a fatty acid chain that binds albumin, extending the half-life to approximately one week.

Available as:

• Ozempic: subcutaneous injection, once weekly, approved for type 2 diabetes
• Wegovy: subcutaneous injection, once weekly, approved for chronic weight management (higher dose than Ozempic)
• Rybelsus: oral tablet, daily, approved for type 2 diabetes

Key clinical evidence:

• STEP 1 (weight management): 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg vs. 2.4% placebo
• SELECT (cardiovascular): 20% reduction in major adverse cardiovascular events (MACE) in overweight/obese adults, the first anti-obesity medication to demonstrate cardiovascular benefit
• SUSTAIN program (diabetes): Consistent HbA1c reductions of 1.5-1.8% across multiple trials

Tirzepatide

Tirzepatide is a dual GLP-1/GIP agonist manufactured by Eli Lilly. It activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.

Available as:

• Mounjaro: subcutaneous injection, once weekly, approved for type 2 diabetes
• Zepbound: subcutaneous injection, once weekly, approved for chronic weight management

Key clinical evidence:

• SURMOUNT-1 (weight management): 20.9% mean weight loss at 72 weeks with tirzepatide 15 mg vs. 3.1% placebo, the highest weight loss achieved by any pharmaceutical intervention
• SURPASS-2 (head-to-head vs. semaglutide): Tirzepatide at all doses produced greater HbA1c reductions and weight loss than semaglutide 1 mg
• SURMOUNT-5 (head-to-head): Tirzepatide 15 mg produced significantly greater weight loss than semaglutide 2.4 mg

Liraglutide

Liraglutide (Victoza for diabetes, Saxenda for weight management) is an older GLP-1 agonist, also by Novo Nordisk. It requires daily injection and produces less weight loss than semaglutide (~8% vs. ~15%). It established the class but has been largely superseded by once-weekly options for new prescriptions.

What About AOD-9604?

AOD-9604 is a fragment of human growth hormone sometimes discussed in weight loss contexts alongside GLP-1 agonists. It works through an entirely different mechanism (lipolysis stimulation) and has substantially less clinical evidence. The comparison is included here because the compounds are sometimes marketed together, but they are not in the same evidence category. See our fat loss guide for detailed comparison.

How They Compare

Semaglutide vs. Tirzepatide

Factor	Semaglutide (Wegovy)	Tirzepatide (Zepbound)
Mechanism	GLP-1 only	GLP-1 + GIP dual
Mean weight loss	~15% (STEP 1)	~21% (SURMOUNT-1)
Dosing	Once weekly SC	Once weekly SC
Cardiovascular data	SELECT trial positive	CVOT pending
GI side effects	Common (~30%)	Common (~30%)
Max dose	2.4 mg	15 mg
Time on market	Longer	Newer

The head-to-head data (SURPASS-2 for diabetes, SURMOUNT-5 for weight) consistently favors tirzepatide for weight loss magnitude. However, semaglutide has the SELECT cardiovascular outcomes data, which tirzepatide does not yet have. Individual response varies, and some patients respond better to one than the other.

Why the GIP addition matters

The role of GIP in weight management was unclear before tirzepatide. GIP receptor knockout mice are obesity-resistant, suggesting GIP promotes fat storage. Yet tirzepatide, which activates the GIP receptor, produces more weight loss than GLP-1 alone. This paradox suggests that pharmacological GIP agonism at supraphysiological levels produces different effects than physiological GIP signaling, a finding that has reshaped understanding of incretin biology.

Important Considerations

Weight regain after discontinuation

Both semaglutide and tirzepatide show significant weight regain after discontinuation. STEP 1 extension data showed approximately two-thirds of lost weight was regained within one year of stopping. SURMOUNT-4 showed similar patterns for tirzepatide. This has led to the medical framing of obesity as a chronic condition requiring ongoing treatment, similar to hypertension.

Muscle mass loss

Significant weight loss from any cause includes lean mass loss. In GLP-1 agonist trials, approximately 25-40% of total weight lost was lean mass (muscle + other non-fat tissue). Whether resistance training fully mitigates this during GLP-1 agonist use is being studied but not yet definitively established. This is a clinically important consideration, particularly for older adults.

Gastrointestinal side effects

Nausea, vomiting, diarrhea, and constipation are the most common side effects across the class. These are generally worst during dose escalation and improve over time. Slow titration reduces their severity and is standard practice.

Serious but rare risks

• Pancreatitis: rare, consistent with class labeling
• Gallbladder disease: increased incidence with rapid weight loss
• Thyroid C-cell tumors: boxed warning based on rodent data (class effect), not confirmed in humans
• Retinopathy worsening: observed in diabetic patients with rapid glucose improvement (semaglutide SUSTAIN-6 data)

For comprehensive safety information, see our peptide safety guide.

The compounding question

The shortage of brand-name GLP-1 agonists has led to significant growth in compounded versions from compounding pharmacies. The FDA has raised concerns about compounded semaglutide and tirzepatide regarding purity, sterility, and potency consistency. Some compounded products have used salt forms (semaglutide sodium) that differ from the approved formulations. This remains an evolving regulatory and safety concern.

Cost and access

GLP-1 agonists are expensive (list prices typically $1,000-1,500/month in the U.S.), and insurance coverage varies. This cost barrier has driven interest in compounded versions and in research peptides like AOD-9604 that are significantly cheaper but have far less evidence. Understanding how to evaluate claims about cheaper alternatives is important for making informed decisions.

How GLP-1 Agonists Differ from Other Peptides on This Site

Readers navigating this site may notice that semaglutide and tirzepatide are discussed very differently from peptides like BPC-157 or ipamorelin. This is not editorial bias — it reflects a genuine difference in evidence quality and regulatory status.

Most peptides covered on PeptideBreakdown exist in the preclinical or early clinical space: animal data, limited human pharmacokinetic studies, and community experience. GLP-1 agonists exist in a fundamentally different evidence tier:

• Trial scale. The SELECT trial for semaglutide enrolled over 17,000 participants. Most research peptides have zero human participants in published trials.
• Regulatory approval. Semaglutide and tirzepatide are FDA-approved, manufactured under cGMP, and prescribed by physicians. They have undergone the full clinical development pipeline.
• Post-marketing data. Millions of prescriptions have been written, generating real-world safety data that no research peptide possesses.
• Insurance coverage. These are reimbursable medications for approved indications — a marker of institutional validation that research peptides do not have.

This difference matters when evaluating information. Claims about semaglutide’s weight loss effects are supported by randomized controlled trials in thousands of people. Claims about BPC-157’s healing effects are supported by animal studies. Both types of evidence are valid, but they are not equivalent. The research methodology guide explains these evidence tiers in detail.

Understanding where a peptide sits on this evidence spectrum is perhaps the single most important skill for anyone navigating peptide information.

Frequently Asked Questions

Which is better, semaglutide or tirzepatide?

Tirzepatide produces greater average weight loss in clinical trials. Semaglutide has proven cardiovascular benefit (SELECT trial). Individual responses vary. The “better” choice depends on the clinical context, insurance coverage, and individual response. Both are effective.

Are GLP-1 agonists peptides?

Yes. Semaglutide and tirzepatide are synthetic peptides (modified analogs of natural GLP-1, a 30-amino acid incretin hormone). They are among the few peptides discussed on this site with full clinical development and FDA approval.

Do you have to take them forever?

Current evidence suggests that weight regain occurs after discontinuation, similar to other chronic disease medications. Some patients maintain partial weight loss long-term. Research into “off-ramping” strategies (dose reduction, intermittent dosing) is ongoing but not yet conclusive.

Can GLP-1 agonists be used for non-diabetic weight loss?

Yes — both semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management in adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity, regardless of diabetes status.

How do GLP-1 agonists compare to other weight loss peptides?

No other peptide has comparable evidence for weight loss. AOD-9604 has limited and disappointing clinical data. Tesamorelin reduces visceral fat specifically but is approved only for HIV-associated lipodystrophy. GLP-1 agonists are in a different evidence tier entirely — see our fat loss peptide guide for detailed comparisons.

What about oral semaglutide?

Rybelsus (oral semaglutide) is available for type 2 diabetes. An oral formulation for weight management at higher doses is in development. Oral bioavailability is limited (requiring large pills taken on an empty stomach with minimal water), but the convenience of oral dosing is appealing for many patients.

References

1. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. PubMed

2. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. PubMed

3. Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. PubMed

4. Frías JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. PubMed

5. Drucker DJ. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. PubMed

Related Articles

Peptide

AOD-9604: Research, Mechanism, and What the Evidence Actually Shows

An evidence-first look at AOD-9604 — the GH fragment studied for fat loss. Clinical trial results, mechanism of action, safety data, and an honest assessment of efficacy.

Peptide

Semaglutide: What the Clinical Evidence Shows About This GLP-1 Agonist

A comprehensive, evidence-first review of semaglutide (Ozempic/Wegovy) — clinical trial data on weight loss and cardiovascular outcomes, mechanism of action, side effects, and practical considerations.

Peptide

Tesamorelin: The FDA-Approved GHRH Analog With Clinical Evidence for Visceral Fat Reduction

An evidence-first review of tesamorelin (Egrifta) — the only currently FDA-approved GHRH analog. Phase III data on visceral fat reduction, emerging cognitive research, and off-label considerations.